{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:47:15Z","timestamp":1778798835624,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Anales de Pediatr\u00eda"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.anpedi.2018.07.007","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T11:36:48Z","timestamp":1534505808000},"page":"141-147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Combinaci\u00f3n de ledipasvir\/sofosbuvir como tratamiento de la infecci\u00f3n cr\u00f3nica por hepatitis C"],"prefix":"10.1016","volume":"90","author":[{"given":"Jes\u00fas","family":"Quintero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Juamp\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ecaterina","family":"Julio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Cabello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Mercadal-Hally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Soler-Palac\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d3scar","family":"Segarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anpedi.2018.07.007_bib0125","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0130","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatol Baltim Md."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.14218\/JCTH.2014.00036","article-title":"Infection in children: Current treatment and new therapies","volume":"3","author":"Lee","year":"2015","journal-title":"J Clin Transl Hepatol."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0140","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jpeds.2013.06.077","article-title":"Perinatal transmission of hepatitis C virus","volume":"163","author":"Indolfi","year":"2013","journal-title":"J Pediatr."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0145","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1002\/hep.1840360714","article-title":"Maternal-infant transmission of hepatitis C virus infection","volume":"36","author":"Roberts","year":"2002","journal-title":"Hepatol Baltim Md."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0150","doi-asserted-by":"crossref","first-page":"7880","DOI":"10.3748\/wjg.v19.i44.7880","article-title":"Burden of pediatric hepatitis C","volume":"19","author":"El-Shabrawi","year":"2013","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0155","first-page":"115","article-title":"Chronic hepatitis C virus infection in children and adolescents: Epidemiology, natural history, and assessment of the safety and efficacy of combination therapy","volume":"1","author":"Indolfi","year":"2010","journal-title":"Adolesc Health Med Ther."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0160","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/MPG.0b013e318258328d","article-title":"NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents","volume":"54","author":"Mack","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0165","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/MPG.0b013e318170af04","article-title":"Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C","volume":"48","author":"Gonz\u00e1lez-Peralta","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0170","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1053\/j.gastro.2008.02.082","article-title":"Long-term course of chronic hepatitis C in children: From viral clearance to end-stage liver disease","volume":"134","author":"Bortolotti","year":"2008","journal-title":"Gastroenterology."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0175","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0180","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0185","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jhep.2010.01.028","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents","volume":"52","author":"Sokal","year":"2010","journal-title":"J Hepatol."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0190","first-page":"878A","article-title":"Pharmacokinetics of once daily sofosbuvir and ledipasvir\/sofosbuvir in HCV-infected pediatrics aged 6 to<12 years old","volume":"64","author":"Garrison","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.anpedi.2018.07.007_bib0195","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/hep.28995","article-title":"The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection","volume":"66","author":"Balistreri","year":"2016","journal-title":"Hepatology."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0200","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/hep.29278","article-title":"Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection","volume":"66","author":"Wirth","year":"2017","journal-title":"Hepatology."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0205","unstructured":"U.S. Food and Drugs Administration. highlights of prescribing information. Sovaldi\u00ae (sofosbuvir) tablets, for oral use [consultado Ene 2016]. Disponible en: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/204671s006lbl.pdf"},{"key":"10.1016\/j.anpedi.2018.07.007_bib0210","unstructured":"U.S. Food and Drugs Administration. Highlights of prescribing information. Harvoni\u00ae tablets, for oral use [consultado Ene 2016]. Disponible en:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/205834s017lbl.pdf"},{"key":"10.1016\/j.anpedi.2018.07.007_bib0215","doi-asserted-by":"crossref","unstructured":"AASLD\/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932-954.","DOI":"10.1002\/hep.27950"},{"key":"10.1016\/j.anpedi.2018.07.007_bib0220","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1365-2893.2010.01381.x","article-title":"Hepatitis C virus infection among healthy Egyptian children: Prevalence and risk factors","volume":"18","author":"Barakat","year":"2011","journal-title":"J Viral Hepat."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0225","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/INF.0b013e318159836c","article-title":"Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection","volume":"27","author":"Jara","year":"2008","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0230","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0235","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med."},{"key":"10.1016\/j.anpedi.2018.07.007_bib0240","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4254\/wjh.v9.i4.180","article-title":"Interferon-free regimens in patients with hepatitis C infection and renal dysfunction or kidney transplantation","volume":"9","author":"Cholongitas","year":"2017","journal-title":"World J Hepatol."}],"container-title":["Anales de Pediatr\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1695403318303175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1695403318303175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T14:48:21Z","timestamp":1761662901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1695403318303175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1695403318303175"],"URL":"https:\/\/doi.org\/10.1016\/j.anpedi.2018.07.007","relation":{},"ISSN":["1695-4033"],"issn-type":[{"value":"1695-4033","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combinaci\u00f3n de ledipasvir\/sofosbuvir como tratamiento de la infecci\u00f3n cr\u00f3nica por hepatitis C","name":"articletitle","label":"Article Title"},{"value":"Anales de Pediatr\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anpedi.2018.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}